Soft Tissue Infections
📧 Sign up to get email alerts when something new happens for Soft Tissue Infections.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2023-05-03Clinical Trial Update: Dalbavancin Outpatient Pilot [Phase 4]
A Phase 4 outpatient pilot trial of dalbavancin was withdrawn.
-
EMA withdrawal · 2010-09-22EMA Refused: Zeftera (previously Zevtera) (ceftobiprole medocaril) — Janssen-Cilag International NV
The EMA refused approval for Zeftera (ceftobiprole medocaril) from Janssen-Cilag International NV for skin and soft tissue infections, with …
-
EMA withdrawal · 2009-10-23EMA Application withdrawn: Mersarex — Arpida A/S
The EMA status shows withdrawal of the Mersarex application by Arpida A/S for skin infections and soft tissue infections.
-
EMA withdrawal · 2009-08-25EMA Application withdrawn: Ramvocid — Targanta Netherlands B.V.
The EMA withdrew the Ramvocid application by Targanta Netherlands B.V. for Gram-positive bacterial infections, skin diseases, and soft tissu…
-
EMA withdrawal · 2008-10-24EMA Application withdrawn: Vibativ (telavancin) — Astellas Pharma Europe B. V.
EMA withdrew the application for Vibativ (telavancin) by Astellas Pharma Europe B. V.; therapeutic areas include skin infections and staphyl…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA withdrawal · 2008-09-10EMA Application withdrawn: Exulett — Pfizer Limited
EMA reports withdrawal of the Exulett application by Pfizer Limited for skin and soft tissue infections and staphylococcal infections.
-
EMA withdrawal · 2007-07-26EMA Application withdrawn: Garenoxacin mesylate — Schering-Plough Europe
The EMA application for garenoxacin mesylate by Schering-Plough Europe was withdrawn.